Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia.

MLA

Tong, Wing H., et al. “Native E. Coli Asparaginase Upfront Should Be Replaced by PEGasparaginase Upfront in the Treatment of Pediatric Patients with Acute Lymphoblastic Leukemia.” Hematological Oncology, vol. 40, no. 4, Oct. 2022, pp. 809–11. EBSCOhost, https://doi.org/10.1002/hon.2960.

APA

Tong, W. H., Mesegué, M., Dapena, J. L., Camós, M., & Rives, S. (2022). Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia. Hematological Oncology, 40(4), 809–811. https://doi.org/10.1002/hon.2960

Chicago

Tong, Wing H., Montserrat Mesegué, José Luís Dapena, Mireia Camós, and Susana Rives. 2022. “Native E. Coli Asparaginase Upfront Should Be Replaced by PEGasparaginase Upfront in the Treatment of Pediatric Patients with Acute Lymphoblastic Leukemia.” Hematological Oncology 40 (4): 809–11. doi:10.1002/hon.2960.